發(fā)布時間：2019-02-12 13:35

【摘要】：目的:卵巢癌肉瘤,不同于一般的卵巢惡性腫瘤,它的發(fā)病率低,約占卵巢惡性腫瘤的1%-2%,但惡性程度高,病人發(fā)病的時候,大部分已屬晚期;該病易復(fù)發(fā),預(yù)后差,目前還沒有統(tǒng)一的明確的治療方案,本臨床分析通過對該病癥狀、體征、實(shí)驗室檢查、影像學(xué)特點(diǎn)、病理特點(diǎn)、治療方案、影響預(yù)后因素進(jìn)行探討,為卵巢癌肉瘤的診斷、治療提供參考。方法:對1997-2017年于廣西醫(yī)科大學(xué)附屬腫瘤醫(yī)院就診的13例以及玉林市腫瘤醫(yī)院1例,玉林市第一人民醫(yī)院1例,柳州市腫瘤醫(yī)院1例,共16例原發(fā)性卵巢癌肉瘤患者的臨床表現(xiàn)、實(shí)驗室檢查、影像學(xué)特點(diǎn)、病理特點(diǎn)、治療方案、影響預(yù)后因素等進(jìn)行回顧性分析。用SPSS17.0統(tǒng)計學(xué)軟件進(jìn)行Kaplan-Meier法生存分析,Log rank檢驗比較生存差異,Cox回歸模型進(jìn)行多變量分析,各分析檢驗方法中以p0.05認(rèn)為有統(tǒng)計學(xué)意義。結(jié)果:1例失訪、9例死亡,其生存期分別是:2、2.5、3.6、3.7、5、12、24.4、40、45、61個月;至末次隨訪,6例存活,其生存期分別是:4.5、7、11.2、22.8、26、46個月�？傮w1、2、5年生存率分別是50%、37.5%、6.25%。I/Ⅱ期1、2、5年生存率分別是87.5%、62.5%、12.5%;Ⅲ/Ⅵ期1、2、5年生存率分別是12.5%、12.5%、0。單因素分析及多因素分析顯示,臨床分期、術(shù)后化療是卵巢癌肉瘤獨(dú)立的預(yù)后因素。結(jié)論:1、卵巢癌肉瘤是一種發(fā)病率低、惡性程度高、易轉(zhuǎn)移、易復(fù)發(fā)、預(yù)后差的腫瘤。2、卵巢癌肉瘤多發(fā)生于絕經(jīng)后女性,多伴有CA125的升高,影像學(xué)表現(xiàn)為盆腔包塊,多數(shù)伴有腹水。3、卵巢癌肉瘤主要治療方法是:腫瘤細(xì)胞減滅術(shù)+含鉑類藥物為基礎(chǔ)的化療。4、臨床分期、術(shù)后化療是影響卵巢癌肉瘤患者預(yù)后的獨(dú)立因素。
[Abstract]:Objective: ovarian cancer sarcoma, which is different from the common ovarian malignant tumor, has a low incidence, accounting for 1- 2 percent of the ovarian malignant tumor, but has a high degree of malignancy. The disease is easy to recur and poor prognosis. There is no unified and definite treatment plan at present. This clinical analysis discussed the symptoms, signs, laboratory examination, imaging features, pathological features, treatment plan and influencing factors of prognosis. To provide reference for diagnosis and treatment of ovarian cancer sarcoma. Methods: from 1997 to 2017, 13 patients in the affiliated Cancer Hospital of Guangxi Medical University, 1 patient in Yulin City tumor Hospital, 1 case in the first people's Hospital of Yulin City and 1 case in Liuzhou Cancer Hospital were studied. The clinical manifestations, laboratory examination, imaging features, pathological features, therapeutic schemes and prognostic factors of 16 patients with primary ovarian cancer sarcoma were retrospectively analyzed. The survival difference was compared by Kaplan-Meier survival analysis, Log rank test with SPSS17.0 statistical software and multivariate analysis with Cox regression model. Results: one case lost the visit, 9 cases died, the survival time was 22.5U 3.6C 3.7U 3.7U 5.1224.4L 4045,61 months, and at the last follow-up, 6 cases survived, the survival time was 4.5U 711.2U 22.8t 26and 46 months respectively. The overall 1 / 2 and 5 year survival rates were 50% and 6. 25% respectively, and the 5 year survival rates were 87.5% (62.5%) and 12.5% (P < 0 05), respectively. The 2-and 5-year survival rates of stage 鈪，

本文編號：2420483